KIYATEC Expands Greenville, South Carolina, Operations
12/17/2021
Located at 2 N. Main Street, the downtown facility will allow the company to expand its existing clinical testing operations and drug development services which are co-located with the Cancer Institute at nearby Prisma Health’s Memorial Campus. The new offices are expected to be operational by January 2022 and the CLIA-certified laboratory by April 2022.
“Securing testing capacity to bring our testing to thousands, then tens of thousands of cancer patients is a business decision that positions us to win and increases our competitive advantage. As a Greenville-based life sciences company, KIYATEC benefits from all this area has to offer including its highly-educated labor force, excellent quality of life for our employees, competitive cost profile and business-friendly environment. We are proud to be a part of the growing business and scientific communities here in Greenville and appreciate the ongoing support from our community leaders in this exciting new phase of our company’s journey.” Said KIYATEC, Inc. CEO Matt Gevaert, Ph.D.
“We’re thrilled to see KIYATEC, Inc. thriving and expanding in South Carolina. The company’s decision to invest $5 million and create 91 new jobs in Greenville County is great news for our state, the Upstate region and our life sciences industry,” noted Secretary of Commerce Harry M. Lightsey III.
Founded in 2005, KIYATEC, Inc. is a commercial stage cancer diagnostics company born from technology developed at Clemson University, creating transformative solutions for cancer patients using functional precision oncology. KIYATEC, Inc. recently launched its first commercial assay 3D Predict™ Glioma for use in glioblastoma (commonly known as GBM) and other brain cancer patient care.
“As a leading functional precision oncology company, KIYATEC is solving medical problems and saving lives through cutting-edge science. Greenville County congratulates KIYATEC on their growth and expansion here in our community, and we wish them continued success,” Greenville County Council Chairman and Greenville Area Development Corporation Board Member Willis Meadows noted.
The company established its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory and began clinical studies in 2015, developing proprietary “ex vivo” 3D cell culture technology platforms to accurately model and predict patient-specific response to approved and investigational cancer drugs targeting a spectrum of solid tumors.
Project Announcements
Archer Plans Vernon, California, Production Operations
05/12/2025
United Arab Emirates-Based Hotpack Plans Edison, New Jersey, Manufacturing Operations
05/12/2025
SSAB Expands Axis, Alabama, Production Operations
05/12/2025
Carnival Corporation Plans Miami, Florida, Headquarters Operations
05/12/2025
Merck Animal Health Expands De Soto, Kansas, Manufacturing Operations
05/12/2025
Oxford Technologies Plans Bay County, Florida, Manufacturing Operations
05/12/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and
Q2 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024